Icon

SOLU-MEDROL (nda011856)- (EQ 40MG BASE/VIAL,EQ 125MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL)

METHYLPREDNISOLONE SODIUM SUCCINATE PHARMACIA AND UPJOHN
EQ 40MG BASE/VIAL,EQ 125MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL
No No
Expired Expired
None None
None No
SOLU-MEDROL Sterile Powder is indicated as follows: *Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. *Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). *Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. *Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. *Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenicpurpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. *Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. *Neoplastic diseases: For the palliative management of leukemias and lymphomas. *Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. *Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. *Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. *Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. *Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
8 0 7
Total Other Developers 8
Drugs with Suitability No
EQ 40MG BASE/VIAL ** ** - - -
EQ 125MG BASE/VIAL ** ** - - -
EQ 500MG BASE/VIAL ** ** - - -
EQ 1GM BASE/VIAL ** ** - - -
EQ 2GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** ****** ****** *************** ******* ******* *********** **** **. **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***. ******, *********, ** ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ******* ******** ******* ******** *************** **., ***. *********** **.***, ******** ****, ****, *******, ******, ***** (***) ***
****** ***** ***** ************ (********), *.* *********** ******* *** ** **, */**/**, ******** ******, ****-***, ******** (***) ***
****** ***** ***** ************ (********), *.* *********** ******* *** ** **, */**/**, ******** ******, ****-***, ******** (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.